Suppr超能文献

钆沉积病:一例报告及退伍军人健康管理局内增强MRI检查的患病率

Gadolinium Deposition Disease: A Case Report and the Prevalence of Enhanced MRI Procedures Within the Veterans Health Administration.

作者信息

Jackson D Bradley, MacIntyre Terence, Duarte-Miramontes Vianey, DeAguero Joshua, Escobar G Patricia, Wagner Brent

机构信息

New Mexico Veterans Administration Health Care System, Albuquerque.

University of New Mexico Health Sciences Center, Albuquerque.

出版信息

Fed Pract. 2022 May;39(5):218-225. doi: 10.12788/fp.0258. Epub 2022 May 14.

Abstract

BACKGROUND

Gadolinium (Gd) usage in the Veterans Health Administration is increasing and patients with renal disease are frequently exposed. Gd is not entirely eliminated within 24 hours after administration, which may pose long-term adverse effects.

CASE PRESENTATION

A Vietnam-era veteran aged > 70 years presented for evaluation of Gd-based contrast agent-induced chronic multisymptom illness. In the course of his routine clinical care, he was exposed to repeated Gd-enhanced magnetic resonance imaging studies. After his second Gd-based contrast agent exposure, he noted rash, pain, headaches, and hoarseness. Years after the exposure to the contrast agents, he continued to have detectable Gd in urine and serum.

CONCLUSIONS

Practitioners should be aware of long-term intracellular Gd retention (including the brain) as patients increasingly turn to consultants with concerns about Gd deposition disease. Data from patient advocates demonstrate that Gd is eliminated in intermediate and long phases, which may represent a multicompartment model. The commercialization of Gd use in imaging studies is outpacing the science addressing the long-term consequences of harboring this alien, toxic, nonphysiologic rare earth metal.

摘要

背景

钆(Gd)在退伍军人健康管理局的使用正在增加,肾病患者经常接触到钆。钆在给药后24小时内不能完全清除,这可能会造成长期不良影响。

病例介绍

一名70多岁的越战老兵前来评估钆基造影剂诱发的慢性多症状疾病。在他的常规临床护理过程中,他多次接受钆增强磁共振成像检查。在第二次接触钆基造影剂后,他出现了皮疹、疼痛、头痛和声音嘶哑。在接触造影剂数年之后,他的尿液和血清中仍可检测到钆。

结论

随着越来越多的患者因担心钆沉积病而向医生咨询,医生应意识到钆在细胞内长期潴留(包括在大脑中)的情况。患者权益倡导者提供的数据表明,钆在中、长期阶段被清除,这可能代表一种多室模型。钆在影像学研究中的商业化应用速度超过了研究这种外来、有毒、非生理性稀土金属长期后果的科学发展速度。

相似文献

4
Gadolinium tissue deposition in the periodontal ligament of mice with reduced renal function exposed to Gd-based contrast agents.
Toxicol Lett. 2019 Feb;301:157-167. doi: 10.1016/j.toxlet.2018.11.014. Epub 2018 Nov 23.
5
[Gadolinium deposition-"gadolinium deposition disease"].
Radiologe. 2019 May;59(5):435-443. doi: 10.1007/s00117-019-0522-9.
10

引用本文的文献

1
Precipitation of gadolinium from magnetic resonance imaging contrast agents may be the Brass tacks of toxicity.
Magn Reson Imaging. 2025 Jun;119:110383. doi: 10.1016/j.mri.2025.110383. Epub 2025 Mar 8.
2
The safety of magnetic resonance imaging contrast agents.
Front Toxicol. 2024 Aug 12;6:1376587. doi: 10.3389/ftox.2024.1376587. eCollection 2024.
3
4
Near-cure in patients with Gadolinium deposition disease undergoing intravenous DTPA chelation.
Front Toxicol. 2024 Jul 25;6:1371131. doi: 10.3389/ftox.2024.1371131. eCollection 2024.

本文引用的文献

1
Gadolinium-Based Contrast Agent Use, Their Safety, and Practice Evolution.
Kidney360. 2020 Jun;1(6):561-568. doi: 10.34067/kid.0000272019. Epub 2020 Jun 25.
2
Physicians with self-diagnosed gadolinium deposition disease: a case series.
Radiol Bras. 2021 Jul-Aug;54(4):238-242. doi: 10.1590/0100-3984.2020.0073.
3
Overlapping roles of NADPH oxidase 4 for diabetic and gadolinium-based contrast agent-induced systemic fibrosis.
Am J Physiol Renal Physiol. 2021 Apr 1;320(4):F617-F627. doi: 10.1152/ajprenal.00456.2020. Epub 2021 Feb 22.
5
An initial investigation of serum cytokine levels in patients with gadolinium retention.
Radiol Bras. 2020 Sep-Oct;53(5):306-313. doi: 10.1590/0100-3984.2019.0075.
7
Risk for Nephrogenic Systemic Fibrosis After Exposure to Newer Gadolinium Agents: A Systematic Review.
Ann Intern Med. 2020 Jul 21;173(2):110-119. doi: 10.7326/M20-0299. Epub 2020 Jun 23.
8
Neurotoxicity from intrathecal gadolinium administration: Case presentation and brief review.
Neurol Clin Pract. 2020 Feb;10(1):e7-e10. doi: 10.1212/CPJ.0000000000000696.
9
Gadolinium-based contrast agents - what is the evidence for 'gadolinium deposition disease' and the use of chelation therapy?
Clin Toxicol (Phila). 2020 Mar;58(3):151-160. doi: 10.1080/15563650.2019.1681442. Epub 2019 Oct 30.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验